| abstract |
IT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: a) A LIPASE INHIBITOR SUCH AS ORLISTAT; b) GLUCOMANAN FROM KONJAC FLOUR (Amorphophallus konjac) AND c) PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS. THE PROPORTION OF THE LIPASE INHIBITOR IS FROM 0.1 TO 20% (p / p), GLUCOMANAN FROM 10 TO 75% (p / p) AND EXCIPIENTS FROM 0.1 TO 90% (p / p). THE EXCIPIENTS ARE SELECTED FROM LOADS, SURFACTANTS, DISINTEGRANTS, BINDERS, LUBRICANTS, FLUIDITY IMPROVERS, SWEETENERS AND COLORANTS. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION, TO A KIT-LIKE EQUIPMENT IN THE FORM OF AN ORAL UNIT DOSAGE. THIS COMPOSITION IS USEFUL IN THE TREATMENT AND PREVENTION OF OBESITY. |